Rhoenix gets emergency clearance for COVID-19 assay

By LabPulse.com staff writers

April 30, 2020 -- The U.S. Food and Drug Administration (FDA) has granted molecular testing company Rhoenix emergency use authorization for a fully automated test to detect the presence of the novel coronavirus from respiratory samples.

The Rheonix COVID-19 MDx assay provides same-day results for COVID-19 testing, according to the company. The automated workflow doesn't need the assistance of a technician and can be done on-site at distributed locations.

The assay is designed for small- and medium-throughput laboratories and is compatible with the company's Encompass MDx workstation. Rheonix said that it has begun shipping both the workstation and test kits to hospital laboratories.

Seasun Biomaterials to launch COVID-19 assay
Seasun Biomaterials plans to release its second COVID-19 assay following emergency use authorization from the U.S. Food Drug Administration.
Erba Mannheim to release ELISA SARS-CoV-2 test kit
Erba Mannheim plans to release an enzyme-linked immunosorbent assay (ELISA) blood test for detecting immunoglobulin G (IgG) and immunoglobulin M (IgM)...
DiaSorin secures EUA for SARS-CoV-2 serology kit
DiaSorin has secured emergency use authorization (EUA) from the U.S. Food and Drug Administration and Biomedical Advanced Research and Development Authority...
Beckman Coulter to release IgG serology test
Beckman Coulter is targeting mid-May for the launch of its new Access SARS-CoV-2 immunoglobulin G (IgG) serology test.
FDA grants emergency authorization for Seegene COVID-19 test
South Korean firm Seegene has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its Allplex COVID-19 assay.

Copyright © 2020 LabPulse.com

Last Updated ls 4/30/2020 4:40:48 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current